logo
Plus   Neg
Share
Email

Vodafone Unveils Vantage Towers; On Track For IPO In Early 2021

Vodafone Group Plc (VOD.L) announced Friday the launch of Vantage Towers, a tower infrastructure platform, which supports Europe's digitalisation by establishing and maintaining extensive, high quality and resilient networks. The company is on track for an Initial Public offering or IPO in early 2021, targeting a Prime Standard Listing in Frankfurt.

The platform will have over 68,000 towers across 9 markets. Vantage Towers is led by Vivek Badrinath as Chief Executive Officer, Thomas Reisten as Chief Financial Officer and Sonia Hernandez as CCO.

The company announced potential to include Vodafone's 50% stake in CTIL, a tower infrastructure company in the UK, with 14,300 towers and 50% share of estimated FY20 pro forma adjusted EBITDA, amounting to 50 million euros to 70 million euros.

The company also announced the merger of Vodafone's and Wind Hellas' towers businesses in Greece, which creates the leading tower infrastructure company in Greece.

Vivek Badrinath, Vantage Towers Chief Executive, said, "I am excited to lead Vantage Towers, which owns the tower infrastructure that is critical for the digital services upon which society, customers and governments rely on across 9 European markets. We have a strong platform to capture growth opportunities in connectivity across Europe, leveraging our long-term arrangements with leading operators."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amid the growing climate crisis, Walmart said it is raising its ambition to zero emissions by 2040, without the use of carbon offsets, across its global operations. The retail giant, along with the Walmart Foundation, also committed to help protect, manage or restore at least 50 million acres of land and one million square miles of ocean by 2030. The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020.
Follow RTT